Top

Published in:

01-03-2019 | Case Report

Posterior Reversible Encephalopathy Syndrome During Treatment with Aflibercept, 5-Fluorouracil, Leucovorin, and Irinotecan for Metastatic Colorectal Cancer

Authors: Nikolaos Miaris, Joseph Sgouros, Margarita Gerolympou, Basilios Spyropoulos, Dionysios Drakopoulos, Stefania Gkoura, Helen Res, Epaminondas Samantas

Published in: Journal of Gastrointestinal Cancer | Issue 1/2019

Excerpt

Posterior reversible encephalopathy syndrome (PRES) is an urgent neurologic condition that is associated with white and gray matter vasogenic edema primarily in parietal and occipital lobes [1]. Clinical features usually involve headache, altered mental status, seizures, and visual disturbances [1]. Although PRES is generally a rare reversible condition, it is increasingly reported in the literature, especially in the setting of cancer patients treated with chemotherapy and antiangiogenic drugs targeting the vascular endothelial growth factor (VEGF) pathway. …

Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14(9):914–25. doi:10.1016/S1474-4422(15)00111-8.CrossRefPubMed

Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499–506. doi:10.1200/JCO.2012.42.8201.CrossRef

Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494–500. doi:10.1056/NEJM199602223340803.CrossRefPubMed

Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. Am J Neuroradiol. 2007;28(7):1320–7. doi:10.3174/ajnr.A0549.CrossRefPubMed

Kamiya-Matsuoka C, Paker AM, Chi L, et al. Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study. J Neuro-Oncol. 2016;128(1):75–84. doi:10.1007/s11060-016-2078-0.CrossRef

Lamy C, Oppenheim C, Mas JL. Posterior reversible encephalopathy syndrome. Handb Clin Neurol. 2014;121:1687–701. doi:10.1016/B978-0-7020-4088-7.00109-7.CrossRefPubMed

Miaris N, Maltezou M, Papaxoinis G, et al. Posterior reversible encephalopathy syndrome with concurrent nephrotic syndrome in a patient treated with pazopanib for metastatic renal cell carcinoma: case report and review of the literature. Clin Genitourin Cancer. 2017; doi:10.1016/j.clgc.2016.08.005.

Tlemsani C, Mir O, Boudou-Rouquette P, et al. Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. Target Oncol. 2011;6(4):253–8. doi:10.1007/s11523-011-0201-x.CrossRefPubMed

Granata G, Greco A, Iannella G, et al. Posterior reversible encephalopathy syndrome—insight into pathogenesis, clinical variants and treatment approaches. Autoimmun Rev. 2015;14(9):830–6. doi:10.1016/j.autrev.2015.05.006.CrossRefPubMed

10.

How J, Blattner M, Fowler S, et al. Chemotherapy-associated posterior reversible encephalopathy syndrome: a case report and review of the literature. Neurologist 2016;21(6):112–7. doi:10.1097/NRL.0000000000000105.

11.

Myint ZW, Sen JM, Watts NL, et al. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature Review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors. Clin Colorectal Cancer. 2017;13(2):127–30. doi:10.1016/j.clcc.2013.12.003.CrossRef

12.

Truman N, Nethercott D. Posterior reversible encephalopathy syndrome (PRES) after treatment with oxaliplatin and 5-fluorouracil. Clin Colorectal Cancer. 2013;12(1):70–2. doi:10.1016/j.clcc.2012.06.003.CrossRefPubMed

13.

Dedić Plavetić N, Rakušić Z, Ozretić D, et al. Fatal outcome of posterior “reversible” encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen. World J Surg Oncol. 2014;12(1):264. doi:10.1186/1477-7819-12-264.CrossRefPubMedPubMedCentral

14.

Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol. 2006;63(10):1475–8. doi:10.1001/archneur.63.10.1475.CrossRefPubMed

15.

Singer S, Grommes C, Reiner AS, et al. Posterior reversible encephalopathy syndrome in patients with cancer. Oncologia. 2015;20:806–11. doi:10.1634/theoncologist.2014-0149.CrossRef

16.

Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci. 2002;99(17):11393–8. doi:10.1073/pnas.172398299.CrossRefPubMed

17.

Ciombor KK, Berlin J, Chan E. Aflibercept. Clin Cancer Res. 2013;19(8):1920–5. doi:10.1158/1078-0432.CCR-12-2911.CrossRefPubMedPubMedCentral

18.

Chen H, Modiano MR, Neal JW, et al. A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. Br J Cancer. 2014;110(3):602–8. doi:10.1038/bjc.2013.735.CrossRefPubMed

19.

Leighl NB, Raez LE, Besse B, et al. A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol. 2010;5(7):1054–9. doi:10.1097/JTO.0b013e3181e2f7fb.CrossRefPubMed

Title: Posterior Reversible Encephalopathy Syndrome During Treatment with Aflibercept, 5-Fluorouracil, Leucovorin, and Irinotecan for Metastatic Colorectal Cancer
Authors: Nikolaos Miaris
Joseph Sgouros
Margarita Gerolympou
Basilios Spyropoulos
Dionysios Drakopoulos
Stefania Gkoura
Helen Res
Epaminondas Samantas
Publication date: 01-03-2019
Publisher: Springer US
Published in: Journal of Gastrointestinal Cancer / Issue 1/2019
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-017-9986-x

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

ACC 2024 Congress

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2019

Expression and Serum Levels of Mucin 5AC (MUC5AC) as a Biomarker for Cholangiocarcinoma: a Meta-analysis

Isolated Metachronous Splenic Metastasis from Colon Cancer: Possible Explanations for This Rare Entity

Is It Possible a Conservative Approach After Radiochemotherapy in Locally Advanced Rectal Cancer (LARC)? A Systematic Review of the Literature and Meta-analysis

Gallbladder Adenocarcinoma as the First Manifestation of Germline BRCA1 Mutation

Therapeutic Challenges in the Management of Bleeding Duodenal Gastrointestinal Stromal Tumor: a Case Report and Review of Literature